Reneo Pharmaceuticals, Inc. is a biopharmaceutical company based in Irvine, CA, dedicated to improving the lives of patients with rare genetic mitochondrial diseases by developing innovative therapies that enhance daily function and quality of life.
With a focus on controlling genes involved in mitochondrial function, Reneo's lead product candidate, mavodelpar (REN001), aims to provide effective treatment options for individuals living with these challenging conditions.
Generated from the website